Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, Shah V, Hoogstraat M, Sei E, Mallo D, Roman-Escorza M, Ahmed AA, Xu M, van den Belt-Dusebout AW, Brugman W, Casasent AK, Clements K, Davies HR, Fu L, Grigoriadis A, Hardman TM, King LM, Krete M, Kristel P, de Maaker M, Maley CC, Marks JR, Menegaz BA, Mulder L, Nieboer F, Nowinski S, Pinder S, Quist J, Salinas-Souza C, Schaapveld M, Schmidt MK, Shaaban AM, Shami R, Sridharan M, Zhang J, Stobart H, Collyar D, Nik-Zainal S, Wessels LFA, Hwang ES, Navin NE, Futreal PA; Grand Challenge PRECISION consortium; Thompson AM, Wesseling J, Sawyer EJ. Lips EH, et al. Among authors: mulder l. Nat Genet. 2022 Jun;54(6):850-860. doi: 10.1038/s41588-022-01082-3. Epub 2022 Jun 9. Nat Genet. 2022. PMID: 35681052 Free PMC article.
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF. de Ronde JJ, et al. Among authors: mulder l. Breast Cancer Res Treat. 2013 Jan;137(1):213-23. doi: 10.1007/s10549-012-2340-x. Epub 2012 Dec 1. Breast Cancer Res Treat. 2013. PMID: 23203637
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.
Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J. Lips EH, et al. Among authors: mulder l. Breast Cancer Res Treat. 2013 Jul;140(1):63-71. doi: 10.1007/s10549-013-2620-0. Epub 2013 Jul 5. Breast Cancer Res Treat. 2013. PMID: 23828499 Free PMC article.
315 results